Morbidity Endpoints (ME) in the Amnog Process in Germany- Are me Less Important in Oncology Substances?
May 1, 2016, 00:00
10.1016/j.jval.2016.03.613
https://www.valueinhealthjournal.com/article/S1098-3015(16)00681-1/fulltext
Title :
Morbidity Endpoints (ME) in the Amnog Process in Germany- Are me Less Important in Oncology Substances?
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)00681-1&doi=10.1016/j.jval.2016.03.613
First page :
A72
Section Title :
Research on Methods - Clinical Outcomes Methods
Open access? :
No
Section Order :
1595